April 17, 2021Open Access

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Key points are not available for this paper at this time.

Clinical Trials.gov NCT01767311 .

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Swanson et al. (Sat,) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: